Anagliptin with metformin and empagliflozin reduces HbA1c in Phase III Korean trial
Adding anagliptin to metformin and empagliflozin lowered HbA1c by 0.57 percentage points more than placebo at 24 weeks in Korean adults with type 2 diabetes.

17 November 2026: Updated on 17 November 2026: treatment differences are now given in percentage points, the conclusion is attributed to the authors, and the India note no longer mentions dapagliflozin, which was not part of this trial.
17 November 2026: Video: the video for this report was re-made to match the correction above.
At a glance
- In a 24-week Phase III trial, adding anagliptin to metformin and empagliflozin lowered HbA1c by 0.57 percentage points more than placebo (95% CI -0.74 to -0.40).
- An HbA1c target of 7.0% or less was attained by 55.7% of participants receiving anagliptin compared with 25.5% on placebo.
- Treatment-emergent adverse events occurred in 22.7% with anagliptin and 17.2% with placebo, with no reported hypoglycaemic events or deaths.
Key result
HbA1c fell by 0.81% with anagliptin versus 0.24% with placebo at Week 24
Change in HbA1c from baseline, Week 24
This report in under a minute
54 seconds · Updated after a correction. Free to use in your CME talks, with credit to Diabesity Rounds. Download the video · captions (SRT).
The study
Hong and colleagues conducted a multicentre, randomised, double-blind, placebo-controlled Phase III trial (ClinicalTrials.gov identifier NCT05814406). The study evaluated the efficacy and safety of anagliptin added to metformin (1000 mg/day or more) plus empagliflozin 10 mg/day in Korean adults with type 2 diabetes who had inadequate glycaemic control.
Participants were randomised 1:1 to receive anagliptin 100 mg twice daily or placebo for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) at Week 24 in the full analysis set, analysed using a mixed-effects model for repeated measures. Secondary endpoints included fasting plasma glucose, HbA1c target attainment, HOMA-β and safety. Glycaemic responder analyses were conducted post hoc. The abstract does not report the funding source.
What they found
The full analysis set included 195 participants, with 97 randomised to anagliptin and 98 to placebo.
At Week 24, least-squares mean HbA1c fell by 0.81% in the anagliptin group and fell by 0.24% in the placebo group. This yielded a statistically significant treatment difference of -0.57 percentage points (95% CI -0.74 to -0.40; p < 0.0001). Fasting plasma glucose was also significantly reduced, with a between-group difference of -12.15 mg/dL (95% CI -19.18 to -5.12; p = 0.0008).
An HbA1c of 7.0% or less was achieved by 55.7% of participants on anagliptin versus 25.5% on placebo. In post hoc analyses, HbA1c reductions of 0.5% or more occurred in 68.0% with anagliptin versus 27.6% with placebo, and reductions of 1.0% or more occurred in 33.0% versus 9.2%. HOMA-β improved significantly with anagliptin (between-group difference 14.35, 95% CI 7.37 to 21.32; p < 0.0001).
Regarding safety, treatment-emergent adverse events occurred in 22.7% of the anagliptin group and 17.2% of the placebo group. No hypoglycaemic events or deaths were reported.
How much weight to give it
This was a randomised, double-blind, placebo-controlled Phase III trial. However, the study was modest in size (195 participants), enrolled only Korean adults and lasted 24 weeks, so longer-term safety and effects in other populations are not known. Additionally, responder analyses were conducted post hoc.
For your clinic
In this trial of adults with type 2 diabetes with inadequate glycaemic control on metformin and empagliflozin 10 mg, the authors concluded that adding anagliptin 100 mg twice daily gave additional HbA1c lowering and improved HOMA-β, with no hypoglycaemic events reported over 24 weeks in this Korean population. Doctors should consult full published trial results and local clinical guidelines when evaluating treatment options for inadequate glycaemic control.
Source
Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Trial.
Hong JH, Lyu YS, Park S et al.. Diabetes, obesity & metabolism. 16 November 2026
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on type 2 diabetes
- Smart insulin pens with bolus calculator lowered HbA1c more than tracking-only pensRandomised trial · 16 November 2026
- Intensive BP control in type 2 diabetes: no significant fall in dementia or MCIRandomised trial · 14 November 2026
- Lacto-vegetarian diet and 14-hour fasting lowered HbA1c in women with T2DMRandomised trial · 13 November 2026
- Tirzepatide vs intensified care in early type 2 diabetes: HbA1c results at week 104Trial registry · 13 November 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.